 | • レポートコード：GIR-105X14151 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、希少神経変性疾患治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。希少神経変性疾患治療の種類別市場規模（神経伝達物質、神経保護剤、生物製剤、その他）、用途別市場規模（筋萎縮性側索硬化症（ALS）、注意欠陥多動性障害（ADHD）、アルツハイマー病、パーキンソン病、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・希少神経変性疾患治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bayer、GlaxoSmithKline、Hoffmann-La Roche、Allergan、Merck KGaA、Johnson and Johnson、Pfizer、Novartis、Sanofi、Teva Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：神経伝達物質、神経保護剤、生物製剤、その他 ・用途別分析2016年-2026年：筋萎縮性側索硬化症（ALS）、注意欠陥多動性障害（ADHD）、アルツハイマー病、パーキンソン病、その他 ・希少神経変性疾患治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・希少神経変性疾患治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・希少神経変性疾患治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・希少神経変性疾患治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・希少神経変性疾患治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Rare Neurodegenerative Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Rare Neurodegenerative Disease Treatment size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Rare Neurodegenerative Disease Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Rare Neurodegenerative Disease Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Market segment by Application can be divided into
Amyotrophic Lateral Sclerosis (ALS)
Attention Deficit Hyperactivity Disorder (ADHD)
Alzheimer’s Disease
Parkinson’s Disease
Others
The key market players for global Rare Neurodegenerative Disease Treatment market are listed below:
Bayer
GlaxoSmithKline
Hoffmann-La Roche
Allergan
Merck KGaA
Johnson and Johnson
Pfizer
Novartis
Sanofi
Teva Pharmaceuticals
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Rare Neurodegenerative Disease Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Rare Neurodegenerative Disease Treatment, with price, sales, revenue and global market share of Rare Neurodegenerative Disease Treatment in 2018 and 2019.
Chapter 3, the Rare Neurodegenerative Disease Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rare Neurodegenerative Disease Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Rare Neurodegenerative Disease Treatment market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Rare Neurodegenerative Disease Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Rare Neurodegenerative Disease Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Rare Neurodegenerative Disease Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Rare Neurodegenerative Disease Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Amyotrophic Lateral Sclerosis (ALS)
1.3.3 Attention Deficit Hyperactivity Disorder (ADHD)
1.3.4 Alzheimer’s Disease
1.3.5 Parkinson’s Disease
1.3.6 Others
1.4 Global Rare Neurodegenerative Disease Treatment Market Size & Forecast
1.4.1 Global Rare Neurodegenerative Disease Treatment Sales in Value (2016-2026))
1.4.2 Global Rare Neurodegenerative Disease Treatment Sales in Volume (2016-2026)
1.4.3 Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2026) & (US$/Unit)
1.5 Global Rare Neurodegenerative Disease Treatment Production Capacity Analysis
1.5.1 Global Rare Neurodegenerative Disease Treatment Total Production Capacity (2016-2026)
1.5.2 Global Rare Neurodegenerative Disease Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Rare Neurodegenerative Disease Treatment Market Drivers
1.6.2 Rare Neurodegenerative Disease Treatment Market Restraints
1.6.3 Rare Neurodegenerative Disease Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Rare Neurodegenerative Disease Treatment Product and Services
2.1.4 Bayer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product and Services
2.2.4 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Hoffmann-La Roche
2.3.1 Hoffmann-La Roche Details
2.3.2 Hoffmann-La Roche Major Business
2.3.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product and Services
2.3.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Allergan
2.4.1 Allergan Details
2.4.2 Allergan Major Business
2.4.3 Allergan Rare Neurodegenerative Disease Treatment Product and Services
2.4.4 Allergan Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Merck KGaA
2.5.1 Merck KGaA Details
2.5.2 Merck KGaA Major Business
2.5.3 Merck KGaA Rare Neurodegenerative Disease Treatment Product and Services
2.5.4 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Johnson and Johnson
2.6.1 Johnson and Johnson Details
2.6.2 Johnson and Johnson Major Business
2.6.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Product and Services
2.6.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Rare Neurodegenerative Disease Treatment Product and Services
2.7.4 Pfizer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Rare Neurodegenerative Disease Treatment Product and Services
2.8.4 Novartis Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Rare Neurodegenerative Disease Treatment Product and Services
2.9.4 Sanofi Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Teva Pharmaceuticals
2.10.1 Teva Pharmaceuticals Details
2.10.2 Teva Pharmaceuticals Major Business
2.10.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product and Services
2.10.4 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Rare Neurodegenerative Disease Treatment Sales by Manufacturer
3.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Rare Neurodegenerative Disease Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Rare Neurodegenerative Disease Treatment Manufacturer Market Share
3.4.2 Top 6 Rare Neurodegenerative Disease Treatment Manufacturer Market Share
3.5 Global Rare Neurodegenerative Disease Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Rare Neurodegenerative Disease Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Rare Neurodegenerative Disease Treatment Market Size by Region
4.1.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2016-2026)
4.2 North America Rare Neurodegenerative Disease Treatment Revenue (2016-2026)
4.3 Europe Rare Neurodegenerative Disease Treatment Revenue (2016-2026)
4.4 Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue (2016-2026)
4.5 South America Rare Neurodegenerative Disease Treatment Revenue (2016-2026)
4.6 Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Type (2016-2026)
5.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2016-2026)
5.3 Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Rare Neurodegenerative Disease Treatment Sales in Volume by Application (2016-2026)
6.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2016-2026)
6.3 Global Rare Neurodegenerative Disease Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2026)
7.2 North America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2026)
7.3 North America Rare Neurodegenerative Disease Treatment Market Size by Country
7.3.1 North America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Rare Neurodegenerative Disease Treatment Sales by Type (2016-2026)
8.2 Europe Rare Neurodegenerative Disease Treatment Sales by Application (2016-2026)
8.3 Europe Rare Neurodegenerative Disease Treatment Market Size by Country
8.3.1 Europe Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Rare Neurodegenerative Disease Treatment Market Size by Region
9.3.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2026)
10.2 South America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2026)
10.3 South America Rare Neurodegenerative Disease Treatment Market Size by Country
10.3.1 South America Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Rare Neurodegenerative Disease Treatment Market Size by Country
11.3.1 Middle East & Africa Rare Neurodegenerative Disease Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Rare Neurodegenerative Disease Treatment Typical Distributors
12.3 Rare Neurodegenerative Disease Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Rare Neurodegenerative Disease Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Rare Neurodegenerative Disease Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. Bayer Basic Information, Manufacturing Base and Competitors
Table 4. Bayer Major Business
Table 5. Bayer Rare Neurodegenerative Disease Treatment Product and Services
Table 6. Bayer Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product and Services
Table 10. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Hoffmann-La Roche Basic Information, Manufacturing Base and Competitors
Table 12. Hoffmann-La Roche Major Business
Table 13. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product and Services
Table 14. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Allergan Basic Information, Manufacturing Base and Competitors
Table 16. Allergan Major Business
Table 17. Allergan Rare Neurodegenerative Disease Treatment Product and Services
Table 18. Allergan Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 20. Merck KGaA Major Business
Table 21. Merck KGaA Rare Neurodegenerative Disease Treatment Product and Services
Table 22. Merck KGaA Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Johnson and Johnson Basic Information, Manufacturing Base and Competitors
Table 24. Johnson and Johnson Major Business
Table 25. Johnson and Johnson Rare Neurodegenerative Disease Treatment Product and Services
Table 26. Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Rare Neurodegenerative Disease Treatment Product and Services
Table 30. Pfizer Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Novartis Basic Information, Manufacturing Base and Competitors
Table 32. Novartis Major Business
Table 33. Novartis Rare Neurodegenerative Disease Treatment Product and Services
Table 34. Novartis Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Sanofi Basic Information, Manufacturing Base and Competitors
Table 36. Sanofi Major Business
Table 37. Sanofi Rare Neurodegenerative Disease Treatment Product and Services
Table 38. Sanofi Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. Teva Pharmaceuticals Major Business
Table 41. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product and Services
Table 42. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Rare Neurodegenerative Disease Treatment Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Rare Neurodegenerative Disease Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Rare Neurodegenerative Disease Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Rare Neurodegenerative Disease Treatment Production Site of Key Manufacturer
Table 48. Rare Neurodegenerative Disease Treatment New Entrant and Capacity Expansion Plans
Table 49. Rare Neurodegenerative Disease Treatment Mergers & Acquisitions in the Past Five Years
Table 50. Global Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021e) & (K Units)
Table 51. Global Rare Neurodegenerative Disease Treatment Sales by Region (2021-2026) & (K Units)
Table 52. Global Rare Neurodegenerative Disease Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Rare Neurodegenerative Disease Treatment Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 55. Global Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 56. Global Rare Neurodegenerative Disease Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Rare Neurodegenerative Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2021e) & (US$/Unit)
Table 59. Global Rare Neurodegenerative Disease Treatment Price by Type (2021-2026) & (US$/Unit)
Table 60. Global Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 61. Global Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 62. Global Rare Neurodegenerative Disease Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Rare Neurodegenerative Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Rare Neurodegenerative Disease Treatment Price by Application (2016-2021e) & (US$/Unit)
Table 65. Global Rare Neurodegenerative Disease Treatment Price by Application (2021-2026) & (US$/Unit)
Table 66. North America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021e) & (K Units)
Table 67. North America Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units)
Table 68. North America Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Rare Neurodegenerative Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 71. North America Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 72. North America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 73. North America Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 74. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021e) & (K Units)
Table 75. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units)
Table 76. Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 79. Europe Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 80. Europe Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 81. Europe Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 82. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2016-2021e) & (K Units)
Table 83. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2021-2026) & (K Units)
Table 84. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 87. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 89. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 90. South America Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021e) & (K Units)
Table 91. South America Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units)
Table 92. South America Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Rare Neurodegenerative Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 95. South America Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 96. South America Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 97. South America Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 98. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Country (2016-2021e) & (K Units)
Table 99. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units)
Table 100. Middle East & Africa Rare Neurodegenerative Disease Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Rare Neurodegenerative Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Type (2016-2021e) & (K Units)
Table 103. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Application (2016-2021e) & (K Units)
Table 105. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Rare Neurodegenerative Disease Treatment Typical Distributors
Table 109. Rare Neurodegenerative Disease Treatment Typical Customers
List of Figures
Figure 1. Rare Neurodegenerative Disease Treatment Picture
Figure 2. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type in 2020
Figure 3. Neurotransmitter Agents
Figure 4. Neuroprotective Agents
Figure 5. Biologics
Figure 6. Others
Figure 7. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application in 2020
Figure 8. Amyotrophic Lateral Sclerosis (ALS)
Figure 9. Attention Deficit Hyperactivity Disorder (ADHD)
Figure 10. Alzheimer’s Disease
Figure 11. Parkinson’s Disease
Figure 12. Others
Figure 13. Global Rare Neurodegenerative Disease Treatment Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 14. Global Rare Neurodegenerative Disease Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Rare Neurodegenerative Disease Treatment Sales (2016-2026) & (K Units)
Figure 16. Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2026) & (US$/Unit)
Figure 17. Global Rare Neurodegenerative Disease Treatment Production Capacity (2016-2026) & (K Units)
Figure 18. Global Rare Neurodegenerative Disease Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Rare Neurodegenerative Disease Treatment Market Drivers
Figure 20. Rare Neurodegenerative Disease Treatment Market Restraints
Figure 21. Rare Neurodegenerative Disease Treatment Market Trends
Figure 22. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Manufacturer in 2020
Figure 23. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Manufacturer in 2020
Figure 24. Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Rare Neurodegenerative Disease Treatment Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Rare Neurodegenerative Disease Treatment Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Region (2016-2026)
Figure 28. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 29. North America Rare Neurodegenerative Disease Treatment Revenue (2016-2026) & (USD Million)
Figure 30. Europe Rare Neurodegenerative Disease Treatment Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue (2016-2026) & (USD Million)
Figure 32. South America Rare Neurodegenerative Disease Treatment Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Rare Neurodegenerative Disease Treatment Revenue (2016-2026) & (USD Million)
Figure 34. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2016-2026)
Figure 35. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2016-2026)
Figure 36. Global Rare Neurodegenerative Disease Treatment Price by Type (2016-2026) & (US$/Unit)
Figure 37. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 38. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2016-2026)
Figure 39. Global Rare Neurodegenerative Disease Treatment Price by Application (2016-2026) & (US$/Unit)
Figure 40. North America Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2016-2026)
Figure 41. North America Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 42. North America Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2016-2026)
Figure 43. North America Rare Neurodegenerative Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 44. United States Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2016-2026)
Figure 48. Europe Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 49. Europe Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2016-2026)
Figure 50. Europe Rare Neurodegenerative Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 51. Germany Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Rare Neurodegenerative Disease Treatment Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 60. China Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2016-2026)
Figure 67. South America Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2016-2026)
Figure 69. South America Rare Neurodegenerative Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Rare Neurodegenerative Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Rare Neurodegenerative Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
神経変性疾患の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to…- クラッベ病治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- 非アルコール性脂肪肝疾患治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-…
- ウィルソン病治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Wilson’s disease is a genetic disorder caused by the loss of function of the ATP7B copper-binding protein that leads to impaired copper transport and excretion, which results in accumulation of free copper in the bloodstream that results in damage of liver, brain, and other organs. As Wilson’s disea…
- 世界の胃食道逆流症（GERD）治療装置市場 2021：企業別、地域別、種類・用途別 The Gastroesophageal Reflux Disease Treatment Device market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain op…